• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Canaccord Genuity initiated coverage on Ocuphire Pharma with a new price target

    2/10/21 7:39:22 AM ET
    $OCUP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUP alert in real time by email
    Canaccord Genuity initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $22.00
    Get the next $OCUP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCUP

    DatePrice TargetRatingAnalyst
    11/24/2021$26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $OCUP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Graves Adrienne L

      4 - Opus Genetics, Inc. (0001228627) (Issuer)

      10/24/24 5:59:15 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bennett Jean was granted 100,000 shares (SEC Form 4)

      4 - Opus Genetics, Inc. (0001228627) (Issuer)

      10/24/24 5:56:44 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Yerxa Benjamin R

      3 - Opus Genetics, Inc. (0001228627) (Issuer)

      10/24/24 5:54:36 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jayagopal Ashwath bought $6,178 worth of shares (3,500 units at $1.76), increasing direct ownership by 5% to 78,500 units (SEC Form 4)

      4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)

      5/24/24 4:07:59 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magrath George bought $8,772 worth of shares (5,000 units at $1.75), increasing direct ownership by 1% to 430,000 units (SEC Form 4)

      4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)

      5/21/24 4:18:02 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schachle Joseph K bought $4,100 worth of shares (2,000 units at $2.05) (SEC Form 4)

      4 - Ocuphire Pharma, Inc. (0001228627) (Issuer)

      3/25/24 4:44:40 PM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Ocuphire Pharma with a new price target

      HC Wainwright & Co. initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $26.00

      11/24/21 6:08:44 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners initiated coverage on Ocuphire Pharma with a new price target

      Alliance Global Partners initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $25.00

      4/5/21 7:14:18 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JonesTrading initiated coverage on Ocuphire Pharma with a new price target

      JonesTrading initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $20.00

      3/29/21 7:30:43 AM ET
      $OCUP
      Biotechnology: Pharmaceutical Preparations
      Health Care